These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. Wilkin A; Pozniak AL; Morales-Ramirez J; Lupo SH; Santoscoy M; Grinsztejn B; Ruxrungtham K; Rimsky LT; Vanveggel S; Boven K; AIDS Res Hum Retroviruses; 2012 May; 28(5):437-46. PubMed ID: 21902621 [TBL] [Abstract][Full Text] [Related]
30. Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication. Zaharatos GJ; Wainberg MA Ann Med; 2013 May; 45(3):236-41. PubMed ID: 23157601 [TBL] [Abstract][Full Text] [Related]
31. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110). Porter DP; Kulkarni R; Fralich T; Miller MD; White KL J Acquir Immune Defic Syndr; 2014 Mar; 65(3):318-26. PubMed ID: 24525469 [TBL] [Abstract][Full Text] [Related]
33. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects. Porter DP; Kulkarni R; Fralich T; Miller MD; White KL HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187 [TBL] [Abstract][Full Text] [Related]
34. Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study. Porter DP; Toma J; Tan Y; Solberg O; Cai S; Kulkarni R; Andreatta K; Lie Y; Chuck SK; Palella F; Miller MD; White KL HIV Clin Trials; 2016 Feb; 17(1):29-37. PubMed ID: 26899540 [TBL] [Abstract][Full Text] [Related]
36. [Rate of genotypic mutations and resistance to antiretroviral drugs in a general hospital]. Fernández Lisón LC; Fernández Pereira LM; Romero Chala S Farm Hosp; 2011; 35(4):191-6. PubMed ID: 21087876 [TBL] [Abstract][Full Text] [Related]
37. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Schiller DS; Youssef-Bessler M Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143 [TBL] [Abstract][Full Text] [Related]
38. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Azijn H; Tirry I; Vingerhoets J; de Béthune MP; Kraus G; Boven K; Jochmans D; Van Craenenbroeck E; Picchio G; Rimsky LT Antimicrob Agents Chemother; 2010 Feb; 54(2):718-27. PubMed ID: 19933797 [TBL] [Abstract][Full Text] [Related]
39. [Conclusions. Position of rilpivirine in the management of infection by the human immunodeficiency virus]. Podzamczer D Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():44. PubMed ID: 24252533 [No Abstract] [Full Text] [Related]
40. Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine. Balamane M; Varghese V; Melikian GL; Fessel WJ; Katzenstein DA; Shafer RW Antimicrob Agents Chemother; 2012 Aug; 56(8):4522-4. PubMed ID: 22664973 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]